91 - Should We Accept This Organ?

Thursday, October 20, 2022

3:15 PM – 4:30 PM US ET

Location: 145 AB

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Moderator(s)

Steven Pergam, MD, MPH

Professor, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center Associate Professor, University of Washington School of Medicine
Fred Hutchinson Cancer Center
Seattle, WA, United States

Disclosure(s): Global Life Technologies, Inc.: Grant/Research Support (Ongoing); Merck and Company, Inc.: Participated in research trial (Terminated)
Maricar Malinis, MD

Associate Professor of Medicine and Transplant (Surgery), Medical Director of Transplant and Oncology ID
Yale School of Medicine
New Haven, CT, United States

Disclosure(s): Aicuris: Primary investigator of clinical trial at Yale site, renumeration goes to institution (Ongoing); Takeda: primary investigator of clinical trial at yale site, renumeration goes to institution (Ongoing)

Faculty(s)

Cameron Wolfe, MBBS, MPH, FIDSA

Associate Professor
Department of Medicine
Duke University
Durham, North Carolina, United States

Disclosure(s): Biogen: Advisor/Consultant (Ongoing); Gilead Biosciences: Advisor/Consultant (Terminated); Janssen Pharmaceuticals: Advisor/Consultant (Ongoing); Regeneron: Advisor/Consultant (Ongoing)

Slides
Stephanie Pouch, MD, MS, FAST

Associate Professor
Division of Infectious Diseases, Department of Medicine
Emory University School of Medicine
Atlanta, GA, United States

Disclosure(s): No financial relationships to disclose

Slides
Ann Woolley, MD, MPH

Associate Clinical Director of Transplant Infectious Diseases
Brigham and Women's Hospital
Boston, MA, United States

Disclosure(s): No financial relationships to disclose

Slides

Disclosure(s):

Steven Pergam, MD, MPH: Global Life Technologies, Inc.: Grant/Research Support (Ongoing); Merck and Company, Inc.: Participated in research trial (Terminated)

Maricar F. Malinis, MD: Aicuris: Primary investigator of clinical trial at Yale site, renumeration goes to institution (Ongoing); Takeda: primary investigator of clinical trial at yale site, renumeration goes to institution (Ongoing)

Cameron R. Wolfe, MBBS, MPH, FIDSA: Biogen: Advisor/Consultant (Ongoing); Gilead Biosciences: Advisor/Consultant (Terminated); Janssen Pharmaceuticals: Advisor/Consultant (Ongoing); Regeneron: Advisor/Consultant (Ongoing)

Stephanie M. Pouch, MD, MS, FAST: No financial relationships to disclose

Ann E. Woolley, MD, MPH: No financial relationships to disclose

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 contact hours of pharmacy CE
ACPE Number: JA0007082-0000-22-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe safe utilization of organs from donors with COVID-19;
discuss interventions to mitigate disease transmission in donors with multidrug-resistant organisms;
apply current treatment and monitoring strategies after transplant for recipients of organs from HCV-positive donors

Presentations:

3:15 PM – 3:40 PM US ET

Can We Accept Organs From Donors With SARS-CoV-2?
Speaker: Cameron R. Wolfe, MBBS, MPH, FIDSA – Duke University
3:40 PM – 4:05 PM US ET

Can We Accept Organs From Donors With Highly Resistant Organisms?
Speaker: Stephanie M. Pouch, MD, MS, FAST – Emory University School of Medicine
4:05 PM – 4:30 PM US ET

How Can We Safely Accept Organs From HCV-Positive Donors?
Speaker: Ann E. Woolley, MD, MPH – Brigham and Women's Hospital